Several other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Oxford Immunotec Global from a buy rating to a hold rating in a report on Thursday, August 1st. ValuEngine lowered shares of Oxford Immunotec Global from a hold rating to a sell rating in a report on Tuesday, July 23rd. Finally, TheStreet lowered shares of Oxford Immunotec Global from a c- rating to a d+ rating in a report on Monday, July 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Oxford Immunotec Global currently has an average rating of Hold and a consensus price target of $18.00.
OXFD opened at $14.54 on Friday. The stock has a 50-day moving average price of $13.42. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. Oxford Immunotec Global has a twelve month low of $11.88 and a twelve month high of $19.19. The company has a market cap of $351.69 million, a price-to-earnings ratio of 28.51 and a beta of 0.33.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The business had revenue of $19.60 million for the quarter, compared to analyst estimates of $19.32 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year. As a group, sell-side analysts predict that Oxford Immunotec Global will post -0.24 EPS for the current fiscal year.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $19.90, for a total transaction of $59,700.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 4.21% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of OXFD. Aperio Group LLC bought a new stake in Oxford Immunotec Global during the 2nd quarter worth about $42,000. BNP Paribas Arbitrage SA grew its holdings in Oxford Immunotec Global by 59,988.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after acquiring an additional 5,399 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Oxford Immunotec Global during the 2nd quarter worth about $173,000. Squarepoint Ops LLC grew its holdings in Oxford Immunotec Global by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after acquiring an additional 5,120 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its holdings in Oxford Immunotec Global by 15.0% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after acquiring an additional 3,255 shares during the last quarter. 91.19% of the stock is currently owned by hedge funds and other institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
See Also: What are no-load funds?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.